Drug development is an arduous process. It can cost from $10 million to $2 billion and take more than 10 years to get a new drug approved after clinical trials. Part of the problem is the inefficiency of animal tests that remain the gold standard in pharmaceutical development. Up to 90% of drugs approved for human use after passing animal tests fail in human trials because humans and animals have different physiologies. A leading biotech company wanted to revolutionize the space, seeing a big promise in organ-on-a-chip technology. Organ-chips are polymer chips that use microfluidic cell structure to mimic human organ functionality and the physiological environment for in vitro disease modeling, drug testing, and precision medicine. With funding support from national institutions, the company developed several organ-on-a-chip platforms with assistance from ITRex that was engaged as a tech partner with experience in embedded IoT software and data analytics solutions.